Related Experiment Video

Updated: May 19, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

New anticoagulants for stroke prophylaxis in atrial fibrillation: assessing the impact on medication adherence

Stephen Kopecky1

  • 1Mayo Clinic, Rochester, MN, USA. kopecky.stephen@mayo.edu

American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|September 6, 2012
PubMed

Insights

Novel anticoagulants like dabigatran, rivaroxaban, and apixaban offer predictable dosing and fewer interactions than warfarin for atrial fibrillation (AF) stroke prevention. Dosing frequency

Area of Science:

  • Cardiology
  • Pharmacology
  • Neurology

Background:

  • Atrial fibrillation (AF) is a common arrhythmia and a major stroke risk factor.
  • Warfarin, a traditional anticoagulant, presents management challenges including dose variability, monitoring, and drug/food interactions.
  • Novel oral anticoagulants (NOACs) offer alternatives with improved predictability and safety profiles.

Purpose of the Study:

  • To compare the characteristics and implications of novel anticoagulants versus warfarin for stroke prophylaxis in AF patients.
  • To highlight the pharmacokinetic-pharmacodynamic predictability of NOACs.
  • To discuss the potential impact of dosing frequency on medication adherence and patient outcomes.

Main Methods:

  • Review of existing literature on anticoagulation for AF.
  • Comparison of warfarin with novel anticoagulants (dabigatran, rivaroxaban, apixaban).
  • Analysis of pharmacokinetic-pharmacodynamic properties, dosing, monitoring, and interaction profiles.

Main Results:

  • NOACs demonstrate predictable pharmacokinetic-pharmacodynamic relationships, enabling fixed dosing and eliminating routine laboratory monitoring.
  • Dabigatran and apixaban are dosed twice daily; rivaroxaban is dosed once daily.
  • NOACs generally have fewer drug and food interactions compared to warfarin.

Conclusions:

  • Novel anticoagulants represent a significant advancement in stroke prevention for AF patients.
  • Fixed dosing and reduced monitoring requirements of NOACs may improve patient management.
  • Dosing frequency's impact on adherence and outcomes warrants further investigation.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.